Last $3.96 USD
Change Today -0.02 / -0.50%
Volume 13.2K
CEMI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

chembio diagnostics inc (CEMI) Snapshot

Open
$4.01
Previous Close
$3.98
Day High
$4.01
Day Low
$3.81
52 Week High
10/27/14 - $5.20
52 Week Low
05/8/14 - $2.83
Market Cap
38.1M
Average Volume 10 Days
47.7K
EPS TTM
$-0.10
Shares Outstanding
9.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMBIO DIAGNOSTICS INC (CEMI)

Related News

No related news articles were found.

chembio diagnostics inc (CEMI) Related Businessweek News

No Related Businessweek News Found

chembio diagnostics inc (CEMI) Details

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company’s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies and antigens. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with the Oswaldo Cruz Foundation relating to products based on its DPP technology products. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

206 Employees
Last Reported Date: 03/6/14
Founded in 1985

chembio diagnostics inc (CEMI) Top Compensated Officers

Chief Operating Officer
Total Annual Compensation: $239.6K
Senior Vice President of Research & Developme...
Total Annual Compensation: $337.1K
Vice President of Regulatory Affairs, Quality...
Total Annual Compensation: $229.8K
Compensation as of Fiscal Year 2013.

chembio diagnostics inc (CEMI) Key Developments

Chembio Diagnostics, Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Chembio Diagnostics, Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. Total revenues for the 2014 third quarter consisted of product sales of $7.25 million compared with $9.04 million in the prior-year period, a decrease of 24.0%. Operating loss for the 2014 third quarter was $262,000 compared with operating income of $1,074,000 for the prior-year period. Net loss for the 2014 third quarter was $271,000, or $0.03 per diluted share, compared with net income of $717,000, or $0.07 per diluted share, for the prior-year period. Loss from operations was $262,473 against income of $1,074,044 a year ago. The total revenues for the 2014 first nine months consisted of product sales of $19.40 million compared with $20.42 million for the prior-year period, a decrease of 5.3%. Operating loss for the 2014 first nine months was $878,000 compared with operating income of $1,181,000 for the prior-year period. Net loss for the 2014 first nine months was $641,000, or $0.07 per diluted share, compared with net income of $793,000, or $0.08 per diluted share, for the prior-year period. Loss from operations was $878,077 against income of $1,180,869 a year ago. Net cash used in operating activities was $5,154,604 against net cash provided by operating activities of $583,808 a year ago. Purchases of fixed assets of $1.06 million.

Chembio Diagnostics, Inc. Receives U.S. Food and Drug Administration Approval for DPP(R) HIV 1/2 Assay

Chembio Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted a CLIA Waiver for the company's DPP(R) HIV 1/2 Assay. Chembio's DPP(R) HIV 1/2 Assay was FDA-approved previously, and the CLIA Waiver will allow Chembio to expand into important new channels that are closest to patient care including physician-office-lab (POL) facilities, clinics and other community healthcare providers. Chembio's DPP(R) HIV 1/2 Assay detects HIV antibodies in oral fluid or blood and uses the Company's patented Dual Path Platform (DPP(R)) technology, which offers excellent sensitivity and specificity. The product's unique SampleTainer(R) specimen collection bottle is a safe, closed system for collecting potentially infectious samples. The DPP(R) HIV 1/2 Assay is one of only two FDA approved, CLIA-waived oral fluid HIV 1/2 rapid tests available in the U.S.

Chembio Diagnostics, Inc. Enters into an Agreements to Develop Point-Of-Care Diagnostic Tests for Dengue Fever Virus and a Specific Type of Cancer

Chembio Diagnostics, Inc. announced that on October 27, 2014 it entered into an agreement to develop a POC diagnostic test for dengue fever virus. The company also announced that it has entered into an agreement with an international diagnostics company to develop a POC diagnostic test for a type of cancer. Both development projects will incorporate Chembio's patented DPP(R) technology. Under the terms of the agreements, financial details and the names of the collaborators are not being disclosed. The DPP(R) point-of-care technology was developed at Chembio, granted initial patent protection in 2007, and has been successfully commercialized as two infectious disease products: DPP(R) HIV 1/2 Assay and DPP(R) HIV-Syphilis Combination Assay. The DPP(R) technology offers a significant advantage over traditional lateral flow technology, as it provides increased sensitivity and the ability to offer multiple test results with a single patient sample.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMI:US $3.96 USD -0.02

CEMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $37.41 USD -0.07
OraSure Technologies Inc $10.28 USD +0.02
Trinity Biotech PLC $17.01 USD +0.03
View Industry Companies
 

Industry Analysis

CEMI

Industry Average

Valuation CEMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMBIO DIAGNOSTICS INC, please visit www.chembio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.